Addictions are chronic brain diseases that can be treated medically
Opiant is a speciality pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
The numbers
More than 20 million people in the United States live with a substance-abuse disorder, but only 10% of those affected receive treatment for their condition
with emergency room visits with Acute Cannabinoid Overdose
with Alcohol Use Disorder
with Opioid Use Disorder and 70k opioid-related overdose deaths annually in the USA
OPIANT AND SUBSTANCE USE DISORDERS
Our Pipeline
To address the diverse and mounting demands of modern-day substance use, Opiant is advancing a pipeline of scientifically-informed treatment approaches.
Spotlight
The latest from Opiant
NBC4 News: Overdose on LA street
October 8, 2021 – Opiant CEO, Dr Roger Crystal, used NARCAN® Nasal Spray to treat a man suffering an apparent opioid overdose on an LA street.
Overdose deaths top 100,000 in a single year
November 18, 2021 – As overdose deaths top 100,000 in a single year, Opiant CEO Dr. Roger Crystal on how fentanyl has worsened the opioid crisis, the importance of overdose preparedness, and Opiant’s work to confront this public health issue.
News Tonight with Chance Seales
October 7, 2021 – In an interview with Chance Seales on News Tonight, Dr. Roger Crystal, Opiant CEO, spoke about the approaches we can take to treat opioid use disorder and opioid overdose in the U.S.
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
SANTA MONICA, Calif. , Jan. 24, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical…
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels 1 Trial is…
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SANTA MONICA, Calif. , Dec. 20, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to…
November 18, 2021 3:00 PM EST : Jefferies Virtual Healthcare London Conference
November 11, 2021 4:30 PM EST : Opiant Pharmaceuticals Third Quarter 2021 Financial Results Conference Call
August 5, 2021 4:30 PM EDT : Opiant Pharmaceuticals Second Quarter 2021 Financial Results Conference Call
Treatment of overdose in the synthetic opioid era
Published in October 2021 by Pharmacology & Therapeutics.
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Lessons from a doctor and CEO on the US’s opioid crisis
April 14, 2020 – Roger Crystal set out to impact healthcare at a ‘societal’ level. The doctor who developed the NARCAN® Nasal Spray says he is proud to see its impact on the opioid crisis in the United States: the opioid overdose reversal medicine has saved a large number of lives.
Opiant donates to organizations supporting patients vulnerable to substance use disorders during COVID-19
Opiant donated $40,000 to the International Association of Fire Fighters Foundation, the Association of Recovery in Higher Education, the Harm Reduction Coalition and the UK’s Action on Addiction.
A Prescription for Tackling the Opioid Overdose Crisis – A Panel Discussion
May 25, 2021 – A panel of experts agreed that to save lives amid the escalating overdose crisis, we must improve education about addiction and overdose, eliminate stigma and rapidly advance co-prescribing of reversal agents.